Company profile
Juvabis AG
Juvabis is a clinical-stage biopharmaceutical startup that develops next-generation antimicrobial therapeutics against highly drug resistant infections. Juvabis holds an exclusive worldwide license for a strong IP portfolio invented at the ETH and University of Zurich by its co-founders. Juvabis has the most advanced antibiotic asset within the Innovative Medicines Initiative ENABLE program, having advanced to Phase-1, first-in-human, clinical trials (scheduled to conclude early 2021). Juvabis currently offers the opportunity for investors to finance Phase 2 clinical trials for its lead asset, whilst advancing the company's preclinical pipeline.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
